CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 79 enrolled
Drug / intervention
leuprolide acetate +2 moredrug
Likely dose
leuprolide acetate 3.75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00687739
NCT00687739Phase 3Completed
CompareCT.gov

Estrogen Deficiency and Mechanisms of Fat Accumulation

University of Colorado, Denver·interventional·Posted Jun 2, 2008·Updated Apr 1, 2025

In Brief

A Phase 3 clinical trial evaluating leuprolide acetate, Estradiol Transdermal, and 1 other intervention for Obesity. Completed, enrolled 79 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate potential mechanisms by which estradiol deficiency accelerates fat gain and abdominal fat accumulation in women.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2, 2008
Enrollment StartMay 1, 2008
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 18.1 years ago

Interventions

leuprolide acetatedrug

3.75 mg for depot suspension delivered by monthly intramuscular injection for 5 months

Estradiol Transdermaldrug

0.075 mg patch per day for 5 months

progressive resistance exercise trainingbehavioral

45 minute exercise sessions 4 times per week for 5 months